R epurposing bacterial CRISPR systems to facilitate RNA-guided cleavage of complementary DNA has revolutionized the field of gene editing in mammalian cells [1] [2] [3] [4] . Streptococcus pyogenes Cas9 has been the most highly used CRISPR system, and its use for genome editing only requires the presence of the Cas9 nuclease and a guide RNA (gRNA). In S. pyogenes, the gRNA is a complex of two species, a universal transactivating crRNA (tracrRNA) and a target-specific crisprRNA (crRNA). The gRNAs can be shortened and fused to result in a 'single guide' RNA (sgRNA). The Cas9-gRNA complex is directed to search for NGG protospacer-adjacent motifs (PAMs) in the genome, and if sufficient complementarity exists between the guide and the target, conformational changes occur and the now fully active Cas9 cleaves the DNA, resulting in a targeted double-stranded break (DSB) 5,6 . The lesion can be healed by the error-prone nonhomologous end-joining (NHEJ) pathway, which often results in creation of an insertion or deletion (indel) of one to several bases 7 . If a homologous donor DNA template is provided during the DSB repair, the homologous recombination (HR) repair pathway can generate more precise changes to the target DNA, including everything from single-nucleotide changes to the insertion of large gene cassettes 8, 9 .
Translation of the CRISPR-Cas9 system to human therapeutics holds high promise. However, specificity remains a concern especially when modifying stem cell populations. We show that existing rationally engineered Cas9 high-fidelity variants have reduced on-target activity when using the therapeutically relevant ribonucleoprotein (RNP) delivery method. Therefore, we devised an unbiased bacterial screen to isolate variants that retain activity in the RNP format. Introduction of a single point mutation, p.R691A, in Cas9 (high-fidelity (HiFi) Cas9) retained the high on-target activity of Cas9 while reducing off-target editing. HiFi Cas9 induces robust AAV6-mediated gene targeting at five therapeutically relevant loci (HBB, IL2RG, CCR5, HEXB, and TRAC) in human CD34 + hematopoietic stem and progenitor cells (HSPCs) as well as primary T cells. We also show that HiFi Cas9 mediates high-level correction of the sickle cell disease (SCD)-causing p.E6V mutation in HSPCs derived from patients with SCD. We anticipate that HiFi Cas9 will have wide utility for both basic science and therapeutic genome-editing applications.
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NATuRE MEDICINE genome editing of autologous HSPCs has the power to be a safe and effective therapy for myriad genetic diseases. Recent studies have shown that hematopoietic disease-causing genetic errors can be corrected in long-term engrafting HSPCs using CRISPR-Cas9 15, 16, 24, 25 . However, there is a risk that Cas9-induced off-target cleavage events could lead to loss of some critical stem cell function, activate oncogenes, or inactivate a tumor suppressor, and this remains a hypothetical concern for translation of this methodology to clinical trials. Although several groups have described novel mutant Cas9 enzymes with reduced off-target cleavage activity [26] [27] [28] , these experiments were performed with plasmid-based Cas9 delivery systems in immortalized cell lines, as opposed to RNP delivery. Therefore, discovery of a Cas9 mutant that does not sacrifice on-target activity while reducing OTEs in the RNP context would have great impact on therapeutic genome editing.
Using an unbiased bacterial screening approach, we identified a single point mutation (p.R691A) in Cas9 that reduces global OTEs while maintaining high on-target activity when used as a RNP complex. We demonstrate that, when compared to HiFi Cas9 (R691A), the rationally designed eSpCas9(1.1) 26 , SpCas9-HF1 (ref. 27 ), and HypaCas9 (ref. 28 ) high-fidelity Cas9 mutants exhibit reduced ontarget editing at many sites when used as a RNP. We demonstrate the clinical utility of HiFi Cas9 in targeting several important disease-associated loci for HR in clinically relevant primary human CD34 + HSPCs and T cells. We also show robust correction of the SCD-causing p.E6V mutation in HSPCs and reduction of OTEs by up to 20-fold relative to wild-type (WT) Cas9.
Results
Existing Cas9 mutants with improved specificity also exhibit reduced on-target activity with RNP delivery. Although delivery of the Cas9-gRNA complex as a RNP can dramatically reduce OTEs, certain guide sequences still cleave off-target sites regardless of the delivery mechanism 15, 16, 29 . We compared the relative on-and off-target cleavage activities using RNP delivery in HEK293 cells for WT Cas9 and two published mutants, eSpCas9(1.1) (p.K848A, p.K1003A, and p.R1060A) or SpCas9-HF1 (p.N497A, p.R661A, p.Q695A, and p.Q926A) 26, 27 at three previously characterized guide sites, VEGFA3, EMX1, and HEKSite4 (Fig. 1a,b ). The eSpCas9(1.1) mutant showed an on-target editing efficiency that was similar to WT Cas9 with the EMX1 guide; however, it only functioned at 60% of the WT level when using both the HEKSite4 or VEGFA3 guides. The SpCas9-HF1 protein had even lower activity at 28% and 12% of the WT level with the HEKSite4 and VEGFA3 guides, respectively ( Fig. 1a,b) . A reduction in Cas9 activity for SpCas9-HF1 and eSp-Cas9(1.1) delivered as a RNP has been previously described, confirming the disadvantage of using these engineered Cas9 variants in the RNP format for high-efficiency gene editing 16, 30 . On-target editing activity in RNP format was further tested using nine guides that target sites within the human HPRT, CTLA4, and PDCD1 genes. The eSpCas9(1.1) mutant on average produced a level of editing activity that was only 23% of WT Cas9, with the best guide in this set producing 56% of the WT activity. The SpCas9-HF1 mutant showed even lower performance and on average produced only 4% of the WT Cas9 editing activity, with the best guide in this set producing 12% of the WT activity ( Fig. 1c ). Thus these mutants, both of which bear multiple amino acid changes, show a pronounced reduction in on-target activity when used with short-duration RNP delivery.
Bacterial selection of new Cas9 mutants maintains on-target editing efficiency while reducing off-target editing. We performed unbiased, high-throughput bacterial selection to identify Cas9 mutants with an improved combination of on-target potency and specificity. We reasoned that mutants selected with this optimization approach would perform well with RNP delivery, which requires that total editing be achieved with transient expression of Cas9 protein. Bacterial screening methods based on positive selection for E. coli have been adapted to isolate Cas9 mutants with altered PAM recognition specificities 31, 32 . In these studies, if Cas9 fails to cleave the on-target plasmid, toxin expression leads to cell lysis, whereas if Cas9 cleaves the on-target plasmid, toxin is not produced and the cells survive and proliferate. We adapted this strategy to select for reduced off-target editing by adding a known off-target site to the Cas9 and sgRNA expression plasmid (that also contained a gene conferring antibiotic resistance) such that surviving colonies represent cells where Cas9 both (i) cleaved the on-target site in the toxin plasmid and (ii) did not cleave the off-target site in the plasmid selecting for antibiotic resistance (Fig. 2a ).
The primary screen was performed using a random Cas9 open reading frame mutant library of ~250,000 clones (average of 5-7 mutations per kb) and on-and off-target site pairs using the VEGFA3 
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guide (Figs. 1b and 2a). We isolated 875 surviving colonies, which were then pooled and used to perform a secondary screen with onand off-target site pairs using the EMX1 guide ( Fig. 2b ). We isolated 163 survivors from the second screen, and DNA sequencing identified 94 amino acid positions where mutations were found at least twice ( Supplementary Fig. 1a ). All 94 humanized Cas9-mutant plasmids were tested in HEK293 cells for both on-and off-target editing efficiency targeting EMX1 or the off-target, problematic HEKSite4 guide ( Supplementary Fig. 1b ,c) 27 . In total, 13 mutants were identified that reduced off-target editing with both EMX1 and HEKSite4 guides and that exhibited an on-target editing efficiency level of at least 50% of that of WT Cas9 (Fig. 2b,c) . Overall, the Cas9-R691S and Cas9-N692D mutants demonstrated the best combination of on-and off-target editing efficiencies ( Fig. 2d,e ). In most cases, alternative substitution of these mutants to alanine yielded a similar or improved phenotype, so we focused on alanine variants for subsequent studies ( Supplementary Fig. 2a,b ). Comparison of the activity of the Cas9-R691A and Cas9-N692A mutants to the previously described high-fidelity Cas9 mutants using the HEKSite4 or EMX1 guides revealed that they induced indels at similar frequencies, suggesting that these single point mutations did not influence on-target activity ( Supplementary Fig. 2c,d) .
The high-fidelity Cas9-R691A mutant demonstrates superior on-target editing with RNP delivery. First, we examined the effects of combinations of mutations using plasmid delivery, and we then tested the most promising single mutants and combinations in RNP format. Although coupling additional mutations to either Cas9-R691A or Cas9-N692A eliminated residual off-target editing in every case tested, a majority of these mutant 
EMX1 HEKSite4
On-target toxin plasmid bacterial selection for cas9 mutants that reduce off-target editing and maintain on-target potency. a, A schematic of bacterial selection process used to isolate Cas9 mutants with reduced off-target editing and high on-target activity. Approximately 250,000 clones were screened for cleavage of the on-target VEGFA3 toxin plasmid and avoidance of cleavage of the off-target plasmid. We isolated 875 surviving colonies from the primary screen, and pooled surviving plasmids were screened a second time using EMX1 guide and target sites. Ultimately 163 Cas9-mutant plasmids were sequenced with mutations at 94 positions occurring twice or more. b,c, Discrimination ratio (on/off-target editing efficiency) of WT Cas9 and all 94 Cas9 point mutations delivered by plasmid into HEK293 cells with the EXM1 (b) or HEKSite4 (c) gRNAs (two-part annealed crRNA:tracrRNA). Horizontal lines indicate the minimum discrimination ratios (indicated numerically above the bars) used to select mutants for further testing. Mutants that maintained greater than 50% on-target editing and reduced off-target editing beyond the limits of detection were arbitrarily set at 30 (EMX1 only) to indicate that they were carried forward into subsequent screening steps. d,e, On-and off-target editing efficiency facilitated by WT and mutant Cas9 plasmids from Fig. 2b ,c examined with crRNAs that target the EMX1 (d) and HEKSite4 (e) delivered via lipofection into HEK293 cells. The on-target site (blue) and off-target site (orange) for each guide are indicated and sequence maps are listed in Fig. 1b . Data are shown as mean ± s.e.m. from n = 9 independent experiments performed at different times. **P < 0.01; ****P < 0.0001; n.s., P ≥ 0.05; two-way ANOVA and Tukey's multiple-comparisons test.
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combinations also compromised on-target editing efficiency, including the Cas9-R691A-N692A double mutant (Supplementary Fig. 2e ). Of note, plasmid-delivered double mutant Cas9-R691A-T740A, Cas9-R691A-S845A, and Cas9-R691A-S872A eliminated off-target editing without influencing efficiency of on-target editing. These results suggest that there can be a tipping point at which optimizing off-target activity can compromise on-target activity.
We then purified promising recombinant single, double, or triple high-specificityCas9 mutants and examined both on-and off-target editing with RNP delivery. On-target editing efficiencies were scrutinized using both a 'low activity' guide, HPRT-38509, that is ideally suited for distinguishing subtle differences in on-target editing efficiency, as well as the HEKSite4 guide. Overall, the Cas9-R691A single mutant exhibited the best overall activity and specificity ( Fig. 3a) . When delivered as a RNP, mutant Cas9-N692A showed a modest but reproducible reduction in on-target editing efficiency relative to Cas9-R691A, which is consistent with prior observations using plasmid-based delivery ( Supplementary Figs. 2a,b ). Interestingly, all recombinant triple mutants tested significantly reduced on-target activity compared to WT Cas9 and Cas9-R691A (hereafter referred to as HiFi Cas9), suggesting that the previously published mutants may have been overengineered to function well as a RNP, as all published mutants have three or more amino acid substitutions.
We further investigated the R691 position by constructing all 19 possible amino acid substitutions, and we tested these mutants via plasmid delivery to evaluate all possible substitutions at this position. Surprisingly, many of these substitutions (13 of 19) maintained good on-target editing efficiency while reducing off-target editing below that of WT Cas9-R691; only the p.R691K and p.R691P mutations failed to improve off-target editing ( Supplementary Fig. 3 ,b). We tested the most promising Cas9 mutants (p.R691D, p.R691G, p.R691H, p.R691Y, and p.R691W) in RNP format, but none showed any improvement over the original Cas9-R691A ( Supplementary Fig. 3c,d) .
A more comprehensive survey was performed to compare the relative on-target activity of the HiFi Cas9-R691A mutant with WT Cas9 and three other mutants with improved fidelity: eSpCas9(1.1), SpCas9-HF1, and HypaCas9 (p.R692A, p.M694A, p.Q695A, and p.H698A) 28 . The five different Cas9 RNPs were tested in HEK293 cells targeting 12 sites within the human HPRT locus with indel detection performed using next-generation sequencing (NGS). The normalized median on-target editing efficiency for each mutant was: 20% for eSpCas9(1.1), 2% for SpCas9-HF1, 1.7% for HypaCas9, and 82% for the HiFi Cas9-R691A mutant (Figs. 3b,3c). A more extended comparison of WT Cas9 versus HiFi Cas9 RNP on-target activity was performed with gRNAs that targeted an additional 48 sites, and these results showed a similar trend-the HiFi Cas9 mutant on average functioned at 92% the efficiency of WT Cas9 ( Supplementary Fig. 3e ). NGS analysis of the indel spectrum between WT and high-fidelity Cas9 mutants indicated that there is no obvious difference in repair outcomes between enzyme variants ( Fig. 3d ). Thus HiFi Cas9-R691A retains editing efficiency comparable to that of WT Cas9 when used in RNP format, whereas the other three previously described Cas9 mutants show reduced editing efficiencies.
Quantitative reduction in off-target editing using the highfidelity mutant. The genome-wide unbiased identification of DSBs enabled by sequencing (GUIDE-seq) procedure 10 can be used to empirically identify real off-target sites in cells. This method relies on DSB capture of short oligonucleotides to 'mark' cleavage events in living cells. GUIDE-seq, although effective at finding offtarget cleavage sites, often yields inconsistent quantitation of lowfrequency editing events. Quantification of off-target editing was therefore done using amplicon-based NGS in separate experiments amplifying sites identified by GUIDE-seq.
The off-target sites for gRNAs that target genes EMX1, AR, HPRT, and HBB were empirically determined using the GUIDE-seq procedure with electroporation of gRNA (10 μ M) and the GUIDEseq tag into HEK293 cells that stably expressed low levels of WT or HiFi Cas9 as a transgene ( Supplementary Fig. 4a,b ). The HiFi Cas9-R691A cell line showed a striking reduction in off-target editing, even with constitutive Cas9 expression ( Supplementary Fig. 4a ). Quantitative assessment of indel frequency was then carried out using multiplex PCR primer pool-based 33 amplicon NGS at the top sites predicted using CRISPOR 34 as well as the GUIDE-seq sites. With constitutive WT Cas9 expression, indel formation at the on-target locus occurred at 95-98% frequency, but there were sufficient OTEs that constituted 28-72% of total editing events ( Fig. 4 ). Constitutive expression of HiFi Cas9, however, maintained 91-99% indel formation at the on-target site, comprising 88-97% of total editing events. Although RNP delivery of WT Cas9 reduced OTEs compared to the WT Cas9 cell line, HiFi Cas9 dramatically reduced off-target editing such that on-target events in every case comprised 99% (or greater) of the total editing events detected. All of the previously reported HiFi Cas9-mutant proteins reduced off-target editing relative to WT Cas9, but OTE reduction occurred at the expense of on-target editing efficiency ( Supplementary Fig. 5 ).
HiFi Cas9 delivered as a RNP is highly active and specific in CD34 + HSPCs. We next examined on-target editing efficiencies of WT, HiFi and other published improved-specificity Cas9 proteins in clinically relevant human primary cells. RNPs were prepared using chemically modified sgRNAs 12 that target disease-causing genes (HBB, CCR5, IL2RG, HEXB, and TRAC), which were then electroporated into CD34 + HSPCs. The HiFi Cas9 mutant demonstrated levels of indel formation across all sites near that of WT Cas9 (~75% of WT Cas9 activity for all five genes) ( Fig. 5a and Supplementary  Fig. 6a ). The previously described improved specificity Cas9 mutants delivered as RNPs showed markedly reduced on-target editing efficiencies, with eSpCas9(1.1) showing less than ~50% of the activity of WT in four out of five genes and the SpCas9-HF1 Cas9 showing less than ~25% of WT efficiency.
As indels are only one measure of a DSB repair (NHEJ), we also tested the capacity of HiFi Cas9 to promote HR in HSPCs. Adenoassociated virus type 6 (AAV6) homologous donor DNA templates are an efficient way to deliver donor templates for sensitive primary immune cells, including HSPCs and T cells 15, [35] [36] [37] [38] [39] [40] . Guides were complexed with either WT, eSpCas9(1.1), SpCas9-HF1, or HiFi Cas9-R691A, electroporated into HSPCs, and then were transduced with gene-specific AAV6 donors. HiFi Cas9 was significantly more active at promoting HR in HSPCs ( > 50% of WT activity at all loci tested) than all of the other high-fidelity Cas9 variants. Of note, eSpCas9(1.1) again was more active than SpCas9-HF1 Cas9 ( Fig. 5b and Supplementary Fig. 6b ). We also examined the performance of the HypaCas9 mutant 28 in targeting HBB with RNP delivery, which likewise showed a significant reduction in on-target editing efficiency ( Supplementary Fig. 6c ). Furthermore, we tested the on-target activity of the newly described evoCas9 (ref. 41 ) (p.M495V, p.Y515N, p.K526E, and p.R661Q) at the EMX1 site with the RNP delivery method and again found severely reduced indel formation compared to WT and HiFi Cas9 ( Supplementary Fig. 6d ). These results imply that HiFi Cas9 is currently the most active and specific high-fidelity Cas9 variant available when delivered as a RNP complex.
The HBB guide site is a good candidate to evaluate the specificity of HiFi Cas9 in HSPCs, as (i) HiFi Cas9 facilitated levels of HR similar to that of WT Cas9 at the on-target locus, (ii) the HBB guide has a known off-target site that persists with RNP delivery, and (iii) the HBB gene is of immediate clinical relevance. Across 11 independent experiments, the HiFi Cas9 mediated a median of 28% HR in comparison to 30% HR for the WT Cas9 ( Fig. 5c and Articles NATuRE MEDICINE Supplementary Fig. 6e ). While maintaining nearly identical ontarget indel activity, the HiFi Cas9 reduced indel frequency at the dominant off-target site by 20-fold ( Fig. 5d,e and Supplementary  Figs. 4b and 6c ). Any reduced HiFi efficiencies could be fully rescued by increasing the concentration of HiFi Cas9 used without adversely affecting specificity or cell viability ( Fig. 5f and data not shown). To ensure that the reduced RNP activity of the three previously published improved-fidelity Cas9 mutants was not influenced by protein purity, stability, or storage effects, we performed extensive quality-characterization assays on the recombinant proteins ( Supplementary Fig. 7 ). Results from these stability studies also support the notion that the HiFi variant has properties well-suited for translational uses, as single lots of protein are stable over time.
Gene knockouts in primary T cells are currently being pursued for therapeutic applications. For example, knockout of the TRAC 
Fig. 3 | The HiFi
Cas9-R691A mutant maintains on-target editing activity when delivered as a RNP. a, On-and off-target editing efficiency of the WT and bacteria-selected mutant Cas9 proteins with crRNAs that target the HEKSite4 and HPRT-38509 loci in HEK293 cells. b, On-target editing efficiency of WT Cas9, eSpCas9(1.1), SpCas9-HF1, HypaCas9, and Cas9-R691A mutant proteins examined using 12 crRNAs that target different sites within the HPRT locus. Numbers included in the target site name indicate the first nucleotide of the target site with respect to the transcription start site of HPRT and S and AS refer to gRNAs that target the sense or antisense strands, respectively. Data are shown as mean ± s.e.m. from n = 3 independent experiments performed at different times. c, Box-and-whiskers plot showing aggregated on-target efficiency data from the eSpCas9(1.1), SpCas9-HF1, HypaCas9, and HiFi Cas9-R691A mutants examined at the HPRT locus in Fig. 3b . The on-target editing efficiencies for each mutant at each site are presented as a percentage of the level of WT Cas9 to account for varying editing efficiencies between guides. Horizontal lines represent the median, upper and lower perimeters mark the 75th and 25th percentiles, and whiskers show the maximum and minimum values, n = 12 from aggregated data in Fig. 3b. d 
Articles
NATuRE MEDICINE
locus is used when generating off-the-shelf allogeneic chimeric antigen receptor-modified T cells (CAR T cells) 42 , and knockout of CCR5 can establish HIV resistance 43 . Therefore, we tested whether the HiFi Cas9 mutant was as active as WT Cas9 in primary human T cells. Human T cells were isolated from buffy coats and were electroporated with CCR5 or TRAC gene specific WT or HiFi RNPs. The HiFi Cas9 showed similar high activity in primary T cells as it did in HSPCs ( Supplementary Fig. 8a ). We also show that AAV6 can be used as a donor template to knock in a CD19-specific CAR T into the TRAC locus ( Supplementary Fig. 8b ), creating potentially nonimmunogenic allogeneic CAR T cells 39, 44 . These results show that the HiFi Cas9 can be used in the context of T cell RNP-based therapeutic genome editing, another indication where a reduced risk for off-target activity is desirable.
HiFi Cas9 delivered as a RNP mediates high-level p.E6V correction while reducing off-target activity in SCD CD34 + HSPCs. SCD is an autosomal recessive red blood cell disorder that is genetically caused by the nucleotide change of an adenine to thymidine in codon 6 of HBB, leading to substitution of glutamic acid by valine (p.E6V) in the beta-globin protein. It is postulated that HR-mediated correction of the HBB gene in autologous HSPCs would be a safe and definitive curative approach for SCD. Accordingly, several reports have shown efficient p.E6V correction in HSPCs derived from patients with SCD (SCD-HSPCs), although correction efficiency can sometimes be linked with off-target indels in the same edited population 15, 16, 45, 46 . SCD-HSPCs were targeted with a sickle corrective ssAAV6 donor 15 by either electroporating HiFi Cas9 or WT Cas9 RNPs. Compared to WT Cas9 editing, the HiFi Cas9 converted a nearly equivalent number of p.E6V alleles (~70% versus ~64%) while reducing off-target cutting by 20-fold ( Fig. 6a,b) . HBB-targeted SCD-HSPCs with WT Cas9 or HiFi Cas9 were differentiated down the erythrocyte lineage 47 and tested for hemoglobin tetramers via cation exchange. Equivalent frequencies of erythrocytes (CD34 -CD45 -CD71 + CD235a + ) 48 and reticulocytes (CD235a + CD49d -Band3 + ) 49 were generated between the HiFi Cas9-and WT Cas9-electroporated samples (Fig. 6c ). Hemoglobin tetramer analyses confirmed the high frequency of p.E6V correction using HiFi Cas9 by showing that > 50% of hemoglobin tetramers produced in targeted differentiated erythrocytes were adult hemoglobin (HbA) (Fig. 6d,e ).
Discussion
Using an unbiased, high-throughput Cas9 mutant screen to select for high on-target and low off-target activity, we identified 
Fig. 5 | RNP HiFi Cas9 facilitates on-target editing potency near the WT level, with large OTe reductions in primary CD34+
HSPCs. a, On-target editing efficiencies of WT Cas9 (normalized dashed line), eSpCas9(1.1), SpCas9-HF1, and HiFi Cas9 mutant proteins examined using chemically modified sgRNAs that target five clinically relevant loci. Cas9 proteins and sgRNAs were delivered as a RNP (1:2.5, Cas9:sgRNA) by nucleofection into CD34 + HSPCs. Indel frequencies were calculated by tracking of indels by decomposition (TIDE). Data are shown as mean ± s.e.m. from n = 3 independent experiments performed in CD34 + cells from three healthy cord blood donors. b, HR frequencies of Cas9 variants that were examined as in Fig.  5a , except following the formation of site-specific Cas9 DSBs, electroporated cells were transduced with ssAAV6 homologous donor templates. For HBB and CCR5, HR was measured via GFP hi expression via FACS; HR at IL2RG and HEXB was measured by assessing allelic-targeted integration via ddPCR; HR at TRAC locus was measured by tNGFR expression. Data are shown as mean ± s.e.m. from n = 3 independent experiments performed in CD34 + cells from three healthy cord blood donors. c, CD34 + HSPCs were electroporated as described above with HBB-targeting gRNAs complexed to either WT or HiFi Cas9, which were then immediately transduced with an HBB-specific rAAV6 (UbC-GFP flanked with HBB homology arms). Cells were harvested and then analyzed for GFP hi expression (which is a measure of homologous recombination) via FACS (n = 11, number of data points within each group, all from different cord blood donors from at least 3 independent experiments). d, CD34 + HSPCs from three healthy donors were electroporated as described above with WT or HiFi HBB-RNPs. HBB (on-target) and the top seven bioinformatically determined and GUIDE-seq-validated regions ( Supplementary Fig. 4b ) were PCR-amplified with sequencing primers used in deep-sequencing MiSeq runs. Data are shown as mean ± s.e.m. from n = 3 independent experiments performed in CD34 + cells from three cord blood donors. e, Indel frequencies in cord blood-derived CD34 + HSPCs that were electroporated with WT or HiFi Cas9 HBB RNPs and cultured for 72-96 h post-electroporation. Data are shown as mean ± s.e.m. of n = 6 data points within each group, all from different cord blood donors from at least three independent experiments performed at different times. f, HSPCs were electroporated with 300 μ g mL −1 WT Cas9 or 300-600 μ g mL −1 HiFi Cas9; half of the cells were transduced with an UbC-GFP ssAAV6 donor, and the other half were cultured. Following 72-96 h post-electroporation, cells were harvested and analyzed for HR by GFP FACS analysis or for off-target indels by TIDE. The lines on the graph show the medians of n = 5 data points within each group from different cord blood donors from at least three independent experiments performed at different times. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001; n.s., P ≥ 0.05; two-way ANOVA and Tukey's multiplecomparisons test. Fig. 6d showing that p.E6V correction in SCD-HSPCs results in HbA protein production when using both the WT and HiFi Cas9 HBB RNPs. This experiment is representative of the three experiments performed in Fig. 6d with similar results.
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gene targeting at therapeutically relevant loci, including correction of the SCD-causing p.E6V mutation in patient-derived cells. Although the previously identified Cas9 mutants with improved specificity do not function as well as the WT or HiFi Cas9 using RNP delivery methods (Figs. 3bc and 5ab and Supplementary Fig. 6 ), these earlier studies do offer important mechanistic insights into how Cas9-sgRNA complexes recognize the target (and off-target) and lead to a DSB. For example, it was originally hypothesized that the eSpCas9(1.1) and SpCas9-HF1 mutants lowered off-target cleavage levels by reducing the relative affinity of the mutant Cas9 nuclease to the substrate DNA. The mutations present in eSpCas9(1.1) affect interactions between the protein and the nontargeted DNA strand, whereas the mutations present in SpCas9-HF1 affect interactions between the protein and the targeted DNA strand. It was theorized that these amino-acid substitutions would further destabilize any mismatches between the gRNA and the substrate DNA 26, 27 . In contrast, it was recently shown that these mutants do not have a decreased affinity for substrate, leading to a new theory that these mutations instead affect transition of Cas9 structure from an inactive conformation to an active conformation and that this transition occurs less efficiently in the presence of mismatches between the RNA guide and the DNA target 28 . These new data led to development of a new variant, HypaCas9, which included four mutations (p.N692A, p.M694A, p.Q695A, and p.H698A) in the REC3 domain. In the present study, the most potent and specific mutation identified was p.R691A, and the second-best mutation identified was p.N692A, which is identical to one of the four sites mutated in the HypaCas9 mutant. It therefore seems likely that HiFi Cas9 improves specificity through a similar mechanism of inhibiting the transition from the inactive to active state in the presence of sgRNA target mismatches. Interestingly, when the p.R691 and p.N692 REC3 point mutations were combined ( Fig.  3a and Supplementary Fig. 2e ), a reduction in on-target activity was observed when used in RNP format. We suspect that the combination of multiple mutations into a single Cas9 variant results in overengineering of the protein that often lowers ontarget catalytic activity when delivered in the RNP format. We propose that the sustained overexpression of both enzyme and sgRNA that results when using plasmid-based systems overcomes this loss of activity and accounts for the discrepancies seen in performance between RNP-based and plasmid-based delivery of these mutants. Experiments with plasmid-based expression of the Cas9 mutants previously described in the literature support this conclusion ( Supplementary Fig. 2c,d ). It will be interesting to see future work that fully characterizes the mechanisms, structure, and conformational changes of the HiFi Cas9 mutant when bound to the target sequence.
Ex vivo RNP-mediated Cas9 genome editing of HSPCs and T cells will likely be some of the first Cas9 editing programs to enter clinical trials within the next few years. While safety and efficacy can only be truly tested in phase 1 clinical trials in humans, using the best possible reagents is important for risk mitigation. We show that HiFi Cas9 has similar on-target efficiency to WT Cas9 but is more specific for mediating HBB gene targeting in primary human HSPCs. Similar studies done examining sites at CCR5, IL2RG, HEXB, and TRAC showed that on-target activity was reduced by as much as ~40%, which was nevertheless still 3-10 times higher than the activity seen using eSpCas9(1.1) and SpCas9-HF1 targeting with AAV6 ( Fig. 5b and Supplementary Fig. 6) . Future experiments will determine whether increasing the amount of HiFi Cas9 can rescue this reduced targeting as it did for HBB ( Fig. 5f) and will also test different combinations of NLS signals to determine whether activity can be improved by improving nuclear localization. While the present work focused primarily on the utility of the HiFi Cas9 in RNP formats, specificity concerns exist when using all methods of Cas9 delivery for any in vivo application. Results obtained from the HEK293-HiFiCas9 cell line that show a reduction in OTEs, even with continuous HiFi Cas9 expression, suggest that the HiFi mutation may similarly have benefit if translated to use in AAV viral vectors 50 , where it will also be constitutively expressed. This benefit should also hold true when HiFi Cas9 mRNA 51, 52 or RNPs 53 is packaged into nanoparticles or even when complexed with cell-penetrating peptides 54 for tissue-specific delivery. We anticipate that future studies will investigate the utility of HiFi Cas9 in these therapeutically relevant contexts.
In conclusion, the new HiFi Cas9 variant will have broad applicability in CRISPR-Cas9 genome editing approaches for both research and clinical purposes.
Methods
Methods, including statements of data availability and any associated accession codes and references, are available at https://doi. org/10.1038/s41591-018-0137-0.
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Methods
Bacterial strains and plasmid construction. Bacterial strain DH5α (F-Φ 80lacZΔ M15 Δ (lacZYA-argF) U169 recA1 endA1 hsdR17 (rK-, mK + ) phoA supE44 λ -thi-1 gyrA96 relA1) was used for routine cloning purposes, and strain BW25141 (ref. 55 ) (F-, Δ(araD-araB)567, ΔlacZ4787(::rrnB-3), Δ(phoB-phoR)580, λ -, galU95, ΔuidA3::pir + , recA1, endA9(del-ins)::FRT, rph-1, Δ(rhaD-rhaB)568, hsdR514) was used for the Cas9 mutagenesis screen. Bacterial strain BL21(DE3) (F-ompT gal dcm lon hsdS B 
[malB + ] K-12 (λ S )) was used for Cas9 protein expression and purification. Relevant plasmids, primers, and gBlocks gene fragments used in this study are listed in Supplementary Tables 1-3 , respectively. The toxin plasmid pIDTV-CcdB was created by subcloning gBlocks (Integrated DNA Technologies, Inc, Coralville, IA, USA) gene fragments encoding lacYA177C and araC-P BAD -ccdB into pUC19. The VEGFA3 or EMX1 on-target sites were introduced into pIDTV-CcdB with site-directed mutagenesis resulting in plasmids pIDTV-CcdB-V3 and pIDTV-CcdB-EMX1, respectively. The Cas9 and VEGFA3 sgRNA expression and off-target site plasmid pIDTV-V3sg-off1 was made by subcloning PCR-amplified cas9 and the V3off1 gBlocks fragment into the NcoI, SacI, and PstI sites of pACYCduet-1 (Millipore Sigma, Burlington, MA, USA). The Cas9 and EMX1 sgRNA expression and EMX1 off-target site plasmid pIDTV-EXsg-off1 was made by subcloning PCRamplified (WT or mutant) cas9 and the EXoff1 gBlocks fragment into the NcoI, SacI, and PstI sites of pACYCduet-1 (Millipore Sigma, Burlington, MA, USA). The commercially available Alt-R S.p. Cas9 Expression Plasmid (Integrated DNA Technologies, Inc) was used for all plasmid-based Cas9 experiments in human cells. Mutations were introduced into the Alt-R S.p. Cas9 Expression Plasmid by site-directed mutagenesis (Supplementary Table 2 ). Unless otherwise indicated, bacteria were grown in lysogeny broth (LB) medium containing the following antibiotics as necessary: carbenicillin (50 μ g mL −1 ), kanamycin (50 μ g mL −1 ), and chloramphenicol (25 μ g mL −1 ). For toxin induction during Cas9-mutant selection, arabinose was added to a final concentration of 0.5% (wt/vol).
E. coli dual selection
Cas9 mutant screen. The basic bacterial selection scheme performed was adapted from a previously described positive selection system for identifying Cas9 mutants in E. coli 31 . E. coli strain BW25141(DE3) was transformed with the pIDTV-CcdB-V3 or pIDTV-CcdB-EMX1 toxin plasmids, and single colonies were verified to permit both carbenicillin resistance and arabinosedependent toxicity. These colonies were used to make electrocompetent cells for screening using ice cold 10% glycerol. A Cas9-mutant library was generated by first amplifying the cas9 gene with low-fidelity PCR using the GeneMorph II random mutagenesis kit (Agilent, Santa Clara, CA, USA), introducing 5-7 mutations per kilobase. The resulting fragments were then subcloned into the pIDTV-V3sg-off1 plasmid to generate a mutant library with less than 1% WT Cas9, as determined by Sanger sequencing. Approximately 250,000 transformants were screened using strain BW25141(DE3) pIDTV-CcdB-V3, yielding 875 surviving colonies for an effective survival rate of 0.35%, significantly above the 0.01% background survival rate of the VEGFA3 on-and off-target site pair. Plasmid DNA from survivors was pooled, and cas9 mutants were subcloned into pIDTV-EXsg-off1 to create a low-complexity library, which was then used to perform a secondary screen with on-and off-target site pairs from EMX1 (Fig. 2b ). Background survival with the EMX1 plasmids indicating that this on-and off-target site pair was more stringent than the VEGFA3 primary screen (data not shown). We screened 20,000 transformants to be > 99% confident that all 875 possible plasmids within the pool were represented at least one time, and 163 survivors were isolated in total ( Supplementary Fig. 1 ).
Isolation and culture of HEK293 cells. The human embryonic kidney cell line HEK293 was used for the majority of HiFi Cas9 development studies. HEK293 cells were cultured in DMEM supplemented with 10% FBS (Thermo Fisher Scientific, Waltham, MA, USA). For routine genome-editing experiments cells were cultured to an average 80-90% confluency and dissociated with trypsin.
Genome editing by plasmid lipofection in HEK293 cells. Plasmid-based genome editing experiments in HEK293 cells were performed with 0.5 μ L per well TransiT-X2 (Mirus Bio, Madison, WI, USA) lipid transfection reagent, 0.1 μ g per well Cas9 human expression plasmid, and 30 nM 1:1 (crRNA:tracrRNA) Alt-R (Integrated DNA Technologies, Inc.) gRNA complex prepared in a volume of 50 μ L total using Opti-MEM reduced serum media (Thermo Fisher Scientific) according to the manufacturer's specifications. Transfections were performed in 96-well plates with 50,000 HEK293 cells in a total volume of 150 μ L using DMEM with 10% FBS, and DNA was extracted 48 h post-transfection using QuickExtract DNA extraction solution (Epicentre Biotechnologies, Madison, WI, USA) according to the manufacturer's specifications. Mutation detection was performed (unless otherwise indicated) with T7 Endonuclease I using the Alt-R Genome Editing Detection Kit (Integrated DNA Technologies, Inc) according to the manufacturer's instructions. For the T7EI assays, both 'cells only' and 'no gRNA' controls were performed for every experiment to assess background levels of indels. Our T7EI experiments were performed only with amplicons that gave no detectable background under these conditions. The targeting sequence for each Cas9 crRNA is listed in Supplementary Table 4 .
Genome editing by RNP lipofection in HEK293 cells. RNP lipofection genome editing experiments in HEK293 cells were performed with 1.2 μ L per well Lipofectamine RNAiMAX lipid transfection reagent and 10 nM (1:1:1, Cas9:crRNA:tracrRNA) Alt-R (Integrated DNA Technologies, Inc) Cas9 RNP complex as described previously 56 . Guide RNAs were prepared according to the manufacturer's instructions and RNPs were formed by the addition of purified Cas9 protein to gRNAs at an equimolar ratio in Opti-MEM with 50 μ L total volume. Complexes were allowed to form for 10 min at room temperature before lipid complex formation. Transfections were performed with 35,000 HEK293 cells in 96-well plates in a volume of 150 μ L total using DMEM with 10% FBS, and DNA was extracted 48 h post-transfection using QuickExtract DNA extraction solution (Epicentre Biotechnologies) according to the manufacturer's specifications. Mutation detection was performed (unless otherwise indicated) with T7 Endonuclease I using the Alt-R Genome Editing Detection Kit (Integrated DNA Technologies, Inc) according to the manufacturer's instructions. PCR cycling parameters for each amplicon consisted of an initial 5-minute incubation at 95 °C, followed by 30 cycles at 98 °C for 20 s, 64-68 °C for 30 s, and 72 °C for 1 minute. The annealing temperature for each amplicon varied for each primer set and is listed in Supplementary 56 . Chemically synthesized gRNAs and crRNAs were prepared according to the manufacturer's instructions, and RNPs were formed by the addition of purified Cas9 protein to gRNAs in 1 × PBS. Complexes were allowed to form for 10 min at room temperature before electroporation. RNP complexes (5 μ L) and 3.5 × 10 5 HEK293 cells (20 μ L) were mixed and electroporated according to the manufacturer's specifications using protocol 96-DS-150. DNA was extracted 48 h post-transfection as described above. The targeting sequence for each Cas9 crRNA is listed in Supplementary Table 4 .
Isolation of HEK293-P CMV -Cas9 stable cell lines. Human codon-optimized
SpCas9 as well as the flanking 5′ and 3′ nuclear localizing sequences and 5′ -V5 tag were digested from the GeneArt CRISPR Nuclease Vector (Thermo Fisher Scientific) using NotI and EcoRI, and this fragment was subcloned into the pcDNA3.1 (-) mammalian expression vector (Thermo Fisher Scientific), resulting in pIDTG-Hs-Int-SpCas9. This plasmid was linearized with the restriction enzyme PvuI (New England Biolabs, Ipswich, MA, USA) at a single site in the ampicillin resistance gene (bla) and transfected into HEK293 cells by lipofection using Lipofectamine 2000 (Thermo Fisher Scientific) for random chromosomal integration. Neomycin-resistant cells were selected using DMEM containing 500 μ g mL −1 G418 (Gibco), and a monoclonal population of cells was isolated by limiting dilution. The resulting stable cell line was determined to have a single copy of the cas9 gene by Droplet Digital PCR (Bio-Rad, Hercules, CA, USA), the correct cas9 sequence by Sanger sequencing, and the inserted fragment was mapped to the X chromosome by inverse PCR 57 . The resulting HEK293-P CMV -Cas9 stable cell line was used as a starting point to make the HiFi R691A substitution to ensure that WT and HiFi cell lines would be otherwise as close to genetically identical as possible with similar expression levels. The p.R691A substitution was introduced into the cas9 gene by HR following Cas9 cleavage by transfecting gRNA and HR donor oligonucleotide by lipofection. A crRNA was used that targets a TGG PAM site located 3-nucleotide (nt) 5′ -adjacent to the R691-CGA arginine codon, and a ssDNA donor oligonucleotide containing symmetrical, 40-nt homology arms corresponding to the nontargeting strand (Supplementary Table 2 ). Monoclonal cell populations were isolated by limiting dilution, and a clone expressing the R691A variant of Cas9 was successfully isolated. The WT and HiFi stable cell lines were confirmed to produce equivalent steady-state Cas9 expression levels ( Supplementary Fig. 4c ). Western blots were performed to compare Cas9 expression levels between WT and HiFi HEK293 stable cell lines using a method that has been described previously 58 . The anti-β -actin (cat. no. ab8226) and anti-SpCas9 (cat. no. ab191468) were both obtained from Abcam. Reactive bands in a western blot were confirmed to be of the correct molecular weight and were dependent on the presence of the corresponding gene.
Expression and purification of Cas9 proteins.
A gBlocks gene fragment (Integrated DNA Technologies, Inc) encoding E. coli codon-optimized S. pyogenes cas9 with a single 5′ SV40 nuclear localization signal (NLS) and dual 3′ SV40 NLS sequences was subcloned into the NcoI and NotI restriction sites of pET28b (Novagen), and the resulting plasmid was called pIDTV-NLS-C9-2NLS-H. Mutations were introduced into this plasmid with site-directed mutagenesis protocols that have been described previously 59 . E. coli Bl21(DE3) carrying pIDTV-NLS-C9-2NLS-H was grown to mid-log phase at 37 °C (OD 600 − 0.6), at which time the culture was chilled to 18 °C and 1 mM isopropyl β -d-1-thiogalactopyranoside (IPTG) was added. Following shaking incubation (250 r.p.m.) at 18 °C for 24 h, cells were collected by centrifugation and lysed 1 nature research | reporting summary 
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Data collection
Prepared DNA libraries were sequenced on an Illumina MiSeq instrument. MiSeq-generated images were converted into nucleotide sequences and base quality scores in the bcl format using Illumina RTA software (v1.18.54).
Data analysis
Data were analyzed using custom-built pipelines. Bcl file data were demultiplexed (Picard tools v2.9; https://github.com/broadinstitute/ picard); forward and reverse reads were merged into extended amplicons (flash v1.2.11); reads were aligned against the GRCh38 genomic reference (bwa v0.7.15), and were assigned to targets in the multiplex primer pool (bedtools v2.25). Reads with any base quality score <10 were filtered out. Editing was calculated as the percentage of total reads containing an INDEL or SNP within a 10bp window of the predicted cut site.
For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.
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March 2018 Narla). The Anti-beta-actin (Cat# ab8226) and Anti-SpCas9 (Cat# ab191468) were both obtained from Abcam. For Cas9, reactive bands in a Western Blot were confirmed to be of the correct molecular weight, and were dependent on the presence of the corresponding gene.
Validation
The antibodies used herein for flow cytometry were validated by using positive (antigen positive cells) and negative (isotype) controls with the recommended antibody concentrations from the manufacturers. All plots are contour plots with outliers or pseudocolor plots.
Eukaryotic cell lines
A numerical value for number of cells or percentage (with statistics) is provided.
Methodology
Sample preparation
Cells were spun down, washed, and analyzed for GFP, or were stained with CD19 or NGFR (CD271).
Instrument
Cells were analyzed for viability and GFP expression using either the Accuri C6 flow cytometer (BD Biosciences) or a FACS Aria II SORP (BD Biosciences) Software FlowJo software was used.
Cell population abundance N/A
Gating strategy
Cells were gated base on FSC/SSC, doublet discrimination, live/dead, and then by GFP, CD19, or NGFR.
Tick this box to confirm that a figure exemplifying the gating strategy is provided in the Supplementary Information.
